Lenvatinib under the microscope: safety check for tough thyroid cancers
NCT ID NCT03573960
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the safety of the drug lenvatinib in 50 people with advanced thyroid cancer that had stopped responding to radioactive iodine treatment. Researchers tracked side effects and how often patients needed to lower their dose. They also checked whether tumors shrank or disappeared. The goal was to confirm that lenvatinib is safe enough for routine use in this hard-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib
What this could lead to
If successful, this study could confirm lenvatinib as a safe and effective option for controlling advanced thyroid cancer that no longer responds to standard treatment.
What could go wrong
This is a small, single-arm study with no comparison group, so results may not be definitive. Side effects like high blood pressure, fatigue, and diarrhea are common and can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, 110029, India
-
All India Institute of Medical Sciences
Bhubaneswar, Odisha, 751019, India
-
BL Kapoor Hospital, New Delhi
New Delhi, 110005, India
-
City Cancer Centre
Vijayawada, 520002, India
-
Deenanath Mangeshkar Hospital
Pune, Maharashtra, 411004, India
-
Indraprastha Apollo Hospital
New Delhi, National Capital Territory of Delhi, 110076, India
-
Indrayani Hospital, Alandi
Pune, 412105, India
-
Regional Cancer Centre, RCC, Thiruvananthapuram
Thiruvananthapuram, Kerala, 695011, India
-
S. P. Medical College & A. G. Hospitals
Bikaner, Rajasthan, 334003, India
-
Shetty's Hospital
Bangalore, Karnataka, 560068, India
-
Tata Memorial Hospital
Mumbai, 400012, India